Corticotropin-releasing factor (CRF) receptor-1 is involved in cardiac noradrenergic activity observed during naloxone-precipitated morphine withdrawal

British Journal of Pharmacology

Volumn 171, Issue 3, 2014, Pages 688-700

  Martínez Laorden, Elena ^a   García Carmona, Juan Antonio ^a   Baroja Mazo, Alberto ^b   Romecín, Paola ^a   Atucha, Noemí M ^a   Milanés, María Victoria ^a   Laorden, María Luisa ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

CRF1 receptor knockout mice; heart; Hsp 27; NA turnover; naloxone precipitated morphine withdrawal

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; HEAT SHOCK PROTEIN 27; MORPHINE; NALOXONE; NORMETADRENALIN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; HEART LEFT VENTRICLE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOBLOTTING; KNOCKOUT MOUSE; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; STRESS; WILD TYPE;

CRF1 RECEPTOR KNOCKOUT MICE; HEART; HSP 27; NA TURNOVER; NALOXONE-PRECIPITATED MORPHINE WITHDRAWAL;

ADRENERGIC NEURONS; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; HEART VENTRICLES; HSP27 HEAT-SHOCK PROTEINS; HYPERTENSION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MORPHINE DEPENDENCE; NALOXONE; NERVE TISSUE PROTEINS; PHOSPHORYLATION; PITUITARY-ADRENAL SYSTEM; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SIGNAL TRANSDUCTION; TACHYCARDIA;

EID: 84892392567     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12511     Document Type: Article

References (63)

1. Alexander SPH, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
2. Almela P, Milanés MV, Laorden ML, (2008). The PKs PKA and ERK 1/2 are involved in phosphorylation of TH at Serine 40 and 31 during morphine withdrawal in rat hearts. Br J Pharmacol 155: 73-83.
3. Almela P, Martínez-Laorden E, Atucha NM, Milanés MV, Laorden ML, (2011). Naloxone-precipitated morphine withdrawal evokes phosphorylation of heat shock protein 27 in rat heart through extracellular signal-regulated kinase. J Mol Cell Cardiol 51: 129-139.
4. Aquaro GD, Gabutti A, Meini M, Prontera C, Pasanisi E, Passino C, et al. (2011). Silent myocardial damage in cocaine addicts. Heart 97: 2056-2062.
5. Arlt J, Jahn H, Kellner M, Strohle A, Yassouridis A, Wiedemann K, (2003). Modulation of sympathetic activity by corticotropin-releasing hormone and atria natriuretic peptide. Endocrinology 37: 362-368.
6. Bale TL, Vale WW, (2004). CRF and CRF receptors: role in stress responsivity and other behaviours. Annu Rev Pharmacol Toxicol 44: 525-557.
7. Basso C, Perazzolo M, Thiene G, (2011). Cocaine and the heart: more than just coronary disease. Heart 97: 1995-1996.
8. Beuten J, Payne TJ, Ma JZ, Li MD, (2005). Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 31: 675-684.
9. Bitar KN, (2002). HSP27 phosphorylation and interaction with actin-myosin in smooth muscle contraction. Am J Physiol Gastrointes Liver Physiol 282: G894-G903.
10. Bornstein SR, Engeland WC, Ehrhart-Bornstein ME, Herman JP, (2008). Dissociation of ACTH and glucocorticoids. Trends Endocrinol Metab 19: 175-180.
11. Bruijnzeel AW, Prado M, Isaac S, (2009). Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse. Biol Psychiatry 66: 110-117.
12. Choi DC, Furai AR, Evanson NK, Ostrander MM, Ulrich-Lai YM, Herman JP, (2007). Bed nucleus of the stria terminalis subregions differentially regulates hypothalamic-pituitary-adrenal axis activity: implications for the integration of limbic inputs. J Neurosci 27: 2025-2034.
13. Chu CP, Qiu DL, Kato K, Kunitake T, Watanabe S, Yu NS, et al. (2004). Central stresscopin modulates cardiovascular function through the adrenal medulla in conscious rats. Regul Pept 119: 53-59.
14. Cobuzzi JL, Riley A, (2011). Spontaneous withdrawal in opiate-dependent Fischer 344, Lewis and Sprague-Dawley rats. Pharmacol Biochem Behav 98: 28-34.
15. Contarino A, Papaleo F, (2005). The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci USA 102: 18649-18654.
16. Corder R, Turnill D, Ling N, Gaillard RC, (1992). Attenuation of corticotropin releasing factor-induced hypotension in anesthetized rats with the CRF antagonist, alpha-helical CRF9-41; comparison with effect on ACTH release. Peptides 13: 1-6.
17. De Souza EB, (1995). Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendrocrinology 20: 789-819.
18. Dettmeyer R, Friedrich K, Schmidt P, Madea B, (2009). Heroin-associated myocardial damages-conventional and immunohistochemical investigations. Forensic Sci Int 187: 42-46.
19. Drastichova Z, Skrabalova J, Jedelsky P, Neckar J, Kolar F, Novotny J, (2012). Global changes in the rat heart proteome induced by prolonged morphine treatment and withdrawal. PLoS ONE 7: e47167.
20. Ersche KD, Roiser JP, Lucas M, Domenici E, Robbins TW, Bullmore ET, (2011). Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology (Berl) 214: 779-789.
21. Frishman WH, Del Vecchio A, Sanal S, Ismail A, (2003). Cardiovascular manifestations of substance abuse: part 2: alcohol, amphetamines, heroin, cannabis, and caffeine. Heart Dis 5: 253-271.
22. Garcia-Carmona JA, Almela P, Baroja-Mazo A, Milanés MV, Laorden ML, (2011). Restricted role of CRF1 receptor for the activity of brainstem catecholaminergic neurons in the negative state of morphine withdrawal. Psychopharmacology (Berl) 220: 379-393.
23. Harris GC, Aston-Jones G, (2007). Activation in extended amygdale corresponds to alter hedonic processing during protracted morphine withdrawal. Behav Brain Res 176: 251-258.
24. Iredale PA, Alvaro JD, Lee Y, Terwilliger R, Chen YL, Duman RS, (2000). Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 74: 199-208.
25. Jiang X, Shi E, Nakajima Y, Sato S, (2006). COX-2 mediates morphine-induced delayed cardioprotection via an iNOS-dependent mechanism. Life Sci 78: 2543-2549.
26. Joels M, Sarabdjitsingh RA, Karst H, (2012). Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol Rev 64: 901-938.
27. Kang YM, Zhang A-Q, Zhao XF, Cardinale JP, Elks C, Cao XM, et al. (2011). Paraventricular nucleus corticotrophin releasing hormone contributes to sympathoexcitation via interaction with neurotransmitters in heart failure. Basic Res Cardiol 106: 473-483.
28. Kasch S, (1987). Serum catecholamines in cocaine intoxicated patients with cardiac symptoms. Ann Emerg Med 16: 481.
29. Kato K, Shinohara H, Goto S, Inaguma Y, Morishita R, Asano T, (1992). Copurification of small heat shock protein alpha B crystallin from human skeletal muscle. J Biol Chem 267: 7718-7725.
30. Kienbaum P, Heuter T, Michel MC, Scherbaum N, Gastpar M, Peters J, (2001). Chronic μ-opioid receptor stimulation in humans decreases muscle sympathetic nerve activity. Circulation 103: 850-855.
31. Kienbaum P, Heuter T, Scherbaum N, Gastpar M, Peters J, (2002). Chronic μ-opioid receptor stimulation alters cardiovascular regulation in humans: differential effects on muscle sympathetic and heart rate responses to arterial hypotension. J Cardiovasc Pharmacol 40: 363-369.
32. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
33. Kishimoto T, Pearse RV, II, Lin CR, Rosenfeld MG, (1995). A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA 92: 1108-1112.
34. Koob G, Kreek MJ, (2007). Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 164: 1149-1159.
35. Koob G, Le Moal M, (2008). Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B 363: 3113-3123.
36. Koob GF, (2008). A role for brain stress system in addiction. Neuron 59: 11-34.
37. Koob GF, (2010). The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res 1314: 3-14.
38. Korosi A, Veening JG, Kozicz T, Henckens M, Dederen J, Groenink L, (2006). Distribution and expression of CRF receptor 1 and 2 mRNAs in the CRF over-expressing mouse brain. Brain Res 1072: 46-45.
39. Li T, Chen CK, Hu X, Ball D, Lin SK, Chen W, et al. (2004). Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet 129B: 120-124.
40. Lu L, Liu D, Geng X, Ma L, (2000). Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12: 4398-4404.
41. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
42. Mackay KB, Stiefel TH, Ling N, Foster AC, (2003). Effects of a selective agonist of CRF(2) receptors on cardiovascular function in the rat. Eur J Pharmacol 469: 111-115.
43. Martínez-Laoden E, Hurle MA, Milanés MV, Laorden ML, Almela P, (2012). Morphine withdrawal actívates hypothalamic-pituitary-adrenal axis and heat shock protein 27 in the left ventricle: the role of extracelular signal regulated kinase. J Pharmacol Exp Ther 342: 665-675.
44. Morimoto A, Nakamori T, Morimoto K, Tan H, Murakami N, (1993). The central role of corticotropin-releasing factor (CRF-41) in psychological stress in rats. J Physiol 460: 221-229.
45. Navarro-Zaragoza J, Nuñez C, Laorden ML, Milanés MV, (2010). Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system response to morphine withdrawal. Mol Pharmacol 77: 864-873.
46. Nerantzis CE, Koulouris SN, Marianou SK, Pastromas SC, Koutsaftis PN, Agapitos EB, (2011). Histologic findings of the sinus node and the perinodal area in street heroin addicts, victims of sudden unexpected death. J Forensic Sci 56: 645-648.
47. Nijsen MJ, Croiset G, Stam R, Bruinjnzeel A, Diamant M, de Wied D, et al. (2000). The role of the CRH type 1 receptor in autonomic responses to corticotropin-releasing hormone in the rat. Neurophsychopharmacology 22: 388-399.
48. Nuñez C, Martín F, Földes A, Laorden ML, Kovács KJ, Milanés MV, (2010). Induction of FosB/?FosB in the brain stress system-related structures during morphine dependence and withdrawal. J Neurochem 114: 475-787.
49. Ongur D, An X, Price JL, (1998). Prefrontal cortical projections to the hypothalamus in macaque monkeys. J Comp Neurol 401: 480-505.
50. Papaleo F, Kitchener P, Contarino A, (2007). Disruption of the CRF/CRF1 receptor stress system exacerbates the somatic signs of opiate withdrawal. Neuron 53: 577-589.
51. Peart JN, Gross GJ, (2006). Cardioprotective effects of acute and chronic opioid treatment is mediated via different signalling pathways. Am J Physiol Heart Circ Physiol 291: H1746-H1753.
52. Pugsley MK, (2002). The diverse molecular mechanism responsible for the actions of opioids on the cardiovascular system. Pharmacol Ther 93: 51-75.
53. Risold PY, Swanson LW, (1997). Connections of the rat lateral septal complex. Brain Res Rev 24: 115-195.
54. Robinson AA, Dunn MJ, McCormack A, dos Remedios C, Rose ML, (2010). Protective effect of phosphorilated Hsp27 in coronary arteries through actin stabilization. J Mol Cell Cardiol 49: 370-379.
55. Sawchenko PE, Swanson LW, (1982). Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat. J Comp Neurol 205: 260-272.
56. Shanazari AAP, Aslani Z, Ramshini E, Alaei H, (2011). Acute and chronic effects of morphine on cardiovascular system and the baroreflexes sensitivity during severe increase in blood pressure in rats. ARYA Atheroscler J 7: 111-117.
57. Tunbridge EM, Huber A, Farrell SM, Stumpenhorst K, Harrison PJ, Walton ME, (2013). The role of cateho-o-methyltransferase in reward processing and addiction. CNS Neurol Disord Drug Targets 11: 306-323.
58. Ueno K, Maeda T, Kiguchi N, Kobayashi Y, Ozaki M, Kishioka S, (2011). Availability of serum corticosterone level for quantitative evaluation of morphine withdrawal in mice. Drug Discov Ther 5: 71-75.
59. Wood SK, McFadden KV, Grigoriadis DG, Bhatnagar S, Valentino RJ, (2012). Depresive and cardiovascular disease comorbidity in a rat model of social stress: a putative role for corticotropin-releasing factor. Psychopharmacology (Berl) 222: 325-336.
60. Xu J, Tian W, Ma X, Guo J, Shi Q, Jin Y, et al. (2011). The molecular mechanism underlying morphine-induced Akt activation: roles of protein phosphatases and reactive oxygen species. Cell Biochem Biophys 61: 303-311.
61. Yang L-Z, Tovote P, Rayner M, Kockskämper J, Pieske B, Spiess J, (2010). Corticotropin-releasing factor receptors and urocortins, links between the brain and the heart. Eur J Pharmacol 632: 1-6.
62. Yoshida-Hiroi M, Bradbury MJ, Eisenhofer G, Hiroi N, Vale WW, Novotny GE, et al. (2002). Chromaffin cell function and structure is impaired in corticotropin-releasing hormone receptor type 1-null mice. Mol Psychiatry 7: 967-974.
63. Yuan Z, McCauley R, Chen-Scarabelli C, Abounit K, Stephanou A, Barry SP, (2010). Activation of Src protein tyrosine kinase plays an essential role in urocortin-mediated cardioprotection. Mol Cell Endocrinol 325: 1-7.